title: [Experiences with monoclonal antibody orthoclone OKT3 following liver transplantation].
abstract: In 7 patients 10 cycles (5 to 21 days, dosage: 30 to 430 mg, median 138 mg) of OKT3 therapy were performed after liver transplantation. In all patients reactivation of an EBV-infection with hepatitis was observed. Two patients treated with high dosages (430 mg respectively 195 mg) developed lymphoproliferative lesions. In one patient with persistent EBV-infection (dosage: 360 mg) a B-cell-lymphoma was diagnosed. This patient died 26 months after transplantation.
authors.affiliation: Chirurgische Universitätsklinik, Universität Hamburg.
authors.forename: H
authors.initials: H
authors.lastname: Kraemer-Hansen
authors.forename: D
authors.initials: D
authors.lastname: Henne-Bruns
authors.forename: S
authors.initials: S
authors.lastname: Schröder
authors.forename: T
authors.initials: T
authors.lastname: Löning
authors.forename: R
authors.initials: R
authors.lastname: Dittmer
authors.forename: B
authors.initials: B
authors.lastname: Kremer
mesh_terms: D005260:Female; D006084:Graft Rejection; D006525:Hepatitis, Viral, Human / Q000382:microbiology*; D004854:Herpesvirus 4, Human / Q000302:isolation & purification*; D006801:Humans; D016031:Liver Transplantation; D016393:Lymphoma, B-Cell / Q000209:etiology; D008232:Lymphoproliferative Disorders / Q000209:etiology; D008297:Male; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000276:immunology; D012008:Recurrence
chemical_list: D016853:Muromonab-CD3
vernacular_title: Erfahrungen mit dem monoklonalen Antikörper Orthoclone OKT3 nach Lebertransplantation.